Lake Street Advisors Group LLC Purchases 406 Shares of Sanofi (NASDAQ:SNY)

Lake Street Advisors Group LLC raised its holdings in shares of Sanofi (NASDAQ:SNY) by 6.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,121 shares of the company’s stock after acquiring an additional 406 shares during the quarter. Lake Street Advisors Group LLC’s holdings in Sanofi were worth $343,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Franklin Resources Inc. raised its holdings in Sanofi by 13.1% during the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after acquiring an additional 395,744 shares in the last quarter. Natixis Advisors LLC increased its position in shares of Sanofi by 4.1% during the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock worth $165,640,000 after purchasing an additional 114,133 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after purchasing an additional 399,301 shares in the last quarter. DAVENPORT & Co LLC boosted its holdings in shares of Sanofi by 40.7% in the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after buying an additional 664,455 shares during the last quarter. Finally, Jennison Associates LLC grew its stake in shares of Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after buying an additional 1,720,972 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Sanofi has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Stock Down 1.5 %

Shares of SNY opened at $54.14 on Friday. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The firm’s 50 day moving average is $51.51 and its 200-day moving average is $52.59. The stock has a market capitalization of $137.40 billion, a PE ratio of 21.74, a P/E/G ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Equities research analysts forecast that Sanofi will post 4.36 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.